South Korea’s Green Cross Cell Corp. said Wednesday its cell therapy manufacturing center has obtained good manufacturing practice (GMP) certification from the Ministry of Food and Drug Safety to start operation.

A GMP certification validates that the center is capable of producing and controlling products consistently according to quality standards.

Built in 2018, the cell therapy manufacturing center is located in Yongin, south of Seoul. The center has four storeys above ground level and two below, with a total floor area of 20,820 square meters. It is the largest of its kind in the country, according to the company.

Green Cross Cell together with parent GC Holdings has invested 110 billion won ($89.8 million) in establishing the cell therapy manufacturing center. They had spent 70 billion won just for setting up cell therapy manufacturing and developing facilities.

The center will produce 20,000 packs of Immuncell-LC, a personalized cancer immunotherapy medicine made from the patient’s blood, annually. Immuncell-LC was approved as a treatment for liver cancer in Korea in 2007.

The cellular therapeutics developer will also scale up the contract manufacturing business.

Shares of Kosdaq-listed Green Gross Cell gained 2.86 percent to 41,350 won on Wednesday.

By Pulse

[ⓒ Pulse by Maeil Business Newspaper & mk.co.kr, All rights reserved]